In 2010, Barnette et al., (2004) have assessed the relationship of MDM2-309T>G polymorphism with AML risk among 575 de novo acute cases treated on three Children’s Oncology Group protocols in USA. Here, MDM2 is linked to acute myeloid leukemia.